Core Insights - BioVaxys Technology Corp. is actively engaging in initiatives for 1Q2026, focusing on collaborations and non-dilutive funding programs [1] Group 1: Government Collaboration - The company is participating in a Request for Information (RFI) by the US Government's Biomedical Advanced Research and Development Authority (BARDA) for new vaccine platforms to address emerging infectious diseases [2] - This RFI is a precursor to a Request for Proposal (RFP), allowing BioVaxys to showcase its DPX platform capabilities early in the process [2] Group 2: International Collaboration - BioVaxys has initiated discussions for a vaccine development collaboration with a UN-chartered organization that has a research budget of nearly US$120 million, targeting diseases like Shigella, Hep B, and Influenza [3] - The attributes of the DPX platform, such as duration of immune activity and micro-dosing capabilities, are highlighted as beneficial for the organization's vaccine development efforts [3] Group 3: Animal Health Collaboration - The company is collaborating with a prospective partner in animal health to evaluate a DPX formulation of a proprietary mRNA sequence for long-duration protection against diseases like rabies [4] - The DPX platform has shown enhanced stability of packaged mRNA and induces specific immune responses, which may lead to new partnerships in the human mRNA vaccine space [4] Group 4: Clinical Study Results - BioVaxys reported positive results from a phase 1 clinical study of MVP-S in breast cancer patients, showing significant systemic antigen-specific T cell responses and a high rate of recurrence-free survival [5] - The company is also reviewing data from an additional phase 1B/2 clinical study with MVP-S and anticipates results soon [6] Group 5: DPX Platform Innovation - The DPX platform represents a significant innovation in vaccine development, utilizing a non-systemic mechanism that enhances immune cell uptake and lymphatic delivery [7] - This approach allows for sustained activation of the immune system, potentially offering advantages over traditional vaccines [7] Group 6: Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on novel immunotherapies for cancers and infectious diseases, utilizing the DPX platform [9] - The company's pipeline includes various products targeting advanced cancers and infectious diseases, demonstrating a commitment to improving patient outcomes [9]